Akari Therapeutics Announces R&D Day on April 24, 2017

NEW YORK and LONDON, March 17th, 2017 — Presentation to Include New Coversin Phase II Data in PNH and Latest Data on Pipeline – Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. The event will […]

Akari Therapeutics to Present at the 29th Annual ROTH Conference

NEW YORK and LONDON, March 7th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the 29th Annual ROTH Conference on March 14th, 2017, in Dana Point, California. The company is scheduled to present at 8:00 a.m. PST. Click here to […]

Akari Therapeutics to Attend Upcoming Investor Conferences in February

NEW YORK and LONDON, January 31st, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will attend and host meetings at two upcoming conferences. • Canaccord Genuity 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017 in New York, NY • Leerink Partners 6th Annual Global […]

Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans

NEW YORK and LONDON, January 4th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its clinical and regulatory teams. In December 2016, Dr. Brihad Abhyankar joined as Head of Clinical Development and Justine Lees joined as European Head of Regulatory Affairs. In January 2017, Nigel A.S. Hernandez, PhD, joined as […]

Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH

NEW YORK and LONDON, January 3rd, 2017 Phase II trial in eculizumab resistant PNH expected to expand into US Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed on December 29th, 2016, its Investigational New Drug Application (IND) for the clinical development […]